Associations between classical Alzheimer's Disease biomarkers and key proteins defining potential pathophysiological mechanisms – A multi‐analyte proteomic analysis

Abstract

Background: Plasma biomarkers like amyloid‐beta Aβ42/Aβ40, p ‐tau isoforms, and NfL are promising for assessing AD risk and pathology. Emerging platforms such as Nucleic Acid‐Linked Immuno‐Sandwich Assay (NULISA) enable precise detection of low‐abundance proteins, offering insights into AD mechanisms.